Lenz Therapeutics Posts Q2 Revenue Fueled by VIZZ Sales and License Agreements
SAN DIEGO—Lenz Therapeutics, Inc. (Nasdaq: LENZ), a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmologic solution) 1.44%, an FDA-approved aceclidine-based eye drop for the treatment of…
